Tyrosine kinase inhibitorFDA-approvedSecond-line
Lorbrena
Generic name: lorlatinib
How it works
Blocks the anaplastic lymphoma kinase (ALK) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, patients with ALK-positive non-small cell lung cancer who received Lorbrena had a response rate of approximately 76%.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Lorlatinib Efficacy and Safety in Lung Cancer Patients | Lung Cancer | observational | The objective response rate was 82.9% in the first-line treatment cohort, and the disease control rate was 100%. The median progression-free survival had not yet been reached in the first-line treatment cohort, and the median progression-free survival was 16.8 months in the subsequent-line treatment cohort. | Source → |
| Lorlatinib Linked to Higher Heart Risks in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Weight Gain Risk for Lung Cancer Patients on Lorlatinib | Lung Cancer | observational | Patients receiving lorlatinib experienced significantly higher maximum weight gain (mean 13.5% [95% confidence interval 10.8-16.2]) | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.